{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:11:08Z","timestamp":1740114668903,"version":"3.37.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"17-18","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.cca.2010.04.014","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T08:37:36Z","timestamp":1272271056000},"page":"1375-1377","source":"Crossref","is-referenced-by-count":9,"title":["Standard warfarin dose in a patient with the CYP2C9*3\/*3 genotype leads to hematuria"],"prefix":"10.1016","volume":"411","author":[{"given":"Toshiharu","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunobu","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Terata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Uno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2010.04.014_bb0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/clpt.1994.139","article-title":"Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic\u2013pharmacodynamic model","volume":"56","author":"Chan","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.clpt.6100316","article-title":"CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study","volume":"83","author":"Caraco","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin","volume":"84","author":"Gage","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0025","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity","volume":"14","author":"Yuan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cca.2010.04.014_bb0030","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-007-0381-6","article-title":"Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients","volume":"63","author":"Miao","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cca.2010.04.014_bb0035","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1373\/clinchem.2006.078139","article-title":"Estimation of warfarin maintenance dose based on VKORC1 (\u22121639G>A) and CYP2C9 genotypes","volume":"53","author":"Zhu","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.04.014_bb0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/GIM.0b013e318163c35f","article-title":"Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin","volume":"10","author":"Flockhart","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.cca.2010.04.014_bb0045","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2010.04.014_bb0050","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clinbiochem.2006.01.023","article-title":"Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort","volume":"39","author":"Moridani","year":"2006","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cca.2010.04.014_bb0055","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cca.2010.04.014_bb0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"De Morais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cca.2010.04.014_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","article-title":"Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population","volume":"12","author":"Fukuen","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cca.2010.04.014_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/FTD.0b013e31805c956e","article-title":"Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation","volume":"29","author":"Uno","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cca.2010.04.014_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2710.2008.00887.x","article-title":"The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers","volume":"33","author":"Uno","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0080","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2010.04.014_bb0085","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2010.04.014_bb0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00008571-200412000-00004","article-title":"Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism","volume":"14","author":"King","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cca.2010.04.014_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/clpt.2009.178","article-title":"Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients","volume":"87","author":"Pautas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clpt.2006.04.010","article-title":"VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients","volume":"80","author":"Obayashi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2006.09.007","article-title":"Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients","volume":"120","author":"Kimura","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.cca.2010.04.014_bb0110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10038-005-0354-5","article-title":"Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients","volume":"51","author":"Mushiroda","year":"2006","journal-title":"J Hum Genet"},{"key":"10.1016\/j.cca.2010.04.014_bb0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-008-0584-5","article-title":"Influence of CYP2C9 genotype on warfarin dose requirements \u2014 a systematic review and meta-analysis","volume":"65","author":"Lindh","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cca.2010.04.014_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3121\/cmr.2007.724","article-title":"Evaluation of genetic factors for warfarin dose prediction","volume":"5","author":"Caldwell","year":"2007","journal-title":"Clin Med Res"},{"key":"10.1016\/j.cca.2010.04.014_bb0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clpt.2005.11.011","article-title":"Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements","volume":"79","author":"Aquilante","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2010.04.014_bb0130","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1373\/clinchem.2009.125898","article-title":"M, Reynolds KK, et al. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy","volume":"55","author":"Linder","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.04.014_bb0135","first-page":"24","article-title":"Warfarin and antidepressants: happiness without hemorrhaging","volume":"6","author":"Sansone","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.cca.2010.04.014_bb0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003088-199700321-00006","article-title":"Effect of sertraline on protein binding of warfarin","volume":"32","author":"Apseloff","year":"1997","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110002718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110002718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:35:46Z","timestamp":1740029746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898110002718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":28,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0009898110002718"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2010.04.014","relation":{},"ISSN":["0009-8981"],"issn-type":[{"type":"print","value":"0009-8981"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}